Shawn Cunningham

Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)

Susan H. Eshleman, Martin Mracna, Laura Guay et al. · AIDS · 2001 · 421 citations

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Characterization of Nevirapine Resistance Mutations in Women With Subtype A Vs. D HIV-1 6???8 Weeks After Single-Dose Nevirapine (HIVNET 012)

Susan H. Eshleman, Laura Guay, Anthony Mwatha et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · 104 citations

Life Sciences, Pharmacotherapy, Molecular Virology +16

Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for Sequence-Based Analysis of Diverse Human Immunodeficiency Virus Type 1 Strains

Susan H. Eshleman, John Hackett, Priscilla Swanson et al. · Journal of Clinical Microbiology · 2004 · 95 citations · Full text

Life Sciences, Infectious Diseases, Molecular Genetics +17

Impact of Human Immunodeficiency Virus Type 1 (HIV‐1) Subtype on Women Receiving Single‐Dose Nevirapine Prophylaxis to Prevent HIV‐1 Vertical Transmission (HIV Network for Prevention Trials 012 Study)

Susan H. Eshleman, Graziella Becker‐Pergola, Martina Deseyve et al. · The Journal of Infectious Diseases · 2001 · 89 citations · Full text

Public Health, Pharmacotherapy, Preventive Medicine +16

Comparison of Nevirapine (NVP) Resistance in Ugandan Women 7 Days vs. 6–8 Weeks after Single-Dose NVP Prophylaxis: HIVNET 012

Susan H. Eshleman, Laura Guay, Anthony Mwatha et al. · AIDS Research and Human Retroviruses · 2004 · 72 citations

Public Health, Maternal Health, Obstetrics +17